Report cover image

Retinal Vein Occlusion Market Report and Forecast 2024-2032

Publisher Expert Market Research
Published Feb 08, 2024
Length 180 Pages
SKU # EMAR18558252

Description

Retinal Vein Occlusion Market Report and Forecast 2024-2032


Retinal Vein Occlusions Market Report and Forecast 2024-2032

Retinal Vein Occlusions Market Outlook

The retinal vein occlusions market size was valued at USD 12.35 billion in 2023, driven by the rising incidence of geriatric population. The market is expected to grow at a CAGR of 13.03% during the forecast period of 2024-2032, with the values likely to attain USD 37.2 billion by 2032.

Retinal Vein Occlusions: Introduction

Retinal vein occlusion (RVO) is a blockage of the small veins that carry blood away from the retina, the layer of tissue at the back of the inner eye. This blockage leads to a buildup of blood and fluid, causing retinal swelling and hemorrhages. RVO results in sudden, painless vision loss or blurring in part or all of one eye. It's associated with conditions like glaucoma, hypertension, and diabetes, and requires prompt medical attention to manage.

Key Trends in the Retinal Vein Occlusions Market

The retinal vein occlusions (RVO) market is advancing rapidly, driven by technological innovations and a growing understanding of the disease. Optical coherence tomography (OCT) imaging is becoming more sophisticated, providing high-resolution images of the retina, which is crucial for accurate diagnosis and monitoring of RVO. These systems offer comprehensive views of the retina, aiding in the assessment and management of peripheral retinal ischemia associated with RVO.

The use of anti-VEGF injections for treating macular edema secondary to RVO is increasing, improving visual outcomes for patients.Implants and injections of corticosteroids are being used for their anti-inflammatory properties to treat macular edema in RVO patients.

Treatments are increasingly being personalized based on the type of RVO (branch or central), severity of the condition, and individual patient response. Development of standardized treatment protocols and algorithms to guide the management of RVO, optimizing patient outcomes.

Increased emphasis on early detection through regular eye examinations, especially for individuals with risk factors such as hypertension, diabetes, or glaucoma. Greater focus on controlling systemic risk factors like hypertension and diabetes to prevent the occurrence or progression of RVO.

A holistic approach to patient management, addressing not just the ocular condition but also associated systemic health issues and psychological well-being is a major market trend. Providing patients with resources and education about RVO, its management, and the importance of adherence to treatment and follow-up visits.

Regulatory bodies are facilitating the approval of innovative treatments and drugs for RVO, expanding the options available to patients. Evolving reimbursement policies are making treatments more accessible to patients, which is crucial for costly long-term therapies like anti-VEGF injections.

Retinal Vein Occlusions Market Segmentation

Market Breakup by Type
  • Branch Retinal Artery Occlusion
  • Central Retinal Vein Occlusion
Market Breakup by Condition
  • Non-Ischemic
  • Ischemic
Market Breakup by Diagnosis
  • Optical Coherence Tomography (OCT)
  • Fundoscopic Examination
  • Fluorescein Angiography
  • Others
Market Breakup by Treatment type
  • Antivascular Endothelial Growth Factor
  • Corticosteroid Drugs
  • Laser Retinal Photocoagulation
  • Others
Market Breakup by End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Retinal Vein Occlusions Market Overview

United States and Canada lead in the adoption of advanced diagnostic and treatment options due to well-established healthcare systems, high patient awareness, and significant investments in healthcare R&D. High prevalence of diabetes and hypertension, major risk factors for RVO, contribute to the demand for treatment. The region also has a strong presence of key market players driving innovation in therapies and diagnostic technologies.

Similar to North America, Western Europe shows a high adoption rate of advanced RVO treatments, supported by strong healthcare infrastructure and active government support for healthcare services. Emphasis on early diagnosis and treatment of RVO, coupled with well-defined regulatory frameworks, supports the market growth. Increasing aging population also contributes to the prevalence of RVO.

Japan, Australia, and South Korea have advanced healthcare systems with growing adoption of the latest RVO treatments, driven by technological advancements and increasing healthcare expenditure. Large patient population and increasing investment in healthcare infrastructure are key growth drivers. However, variability in access to advanced healthcare and economic disparities can affect market dynamics.

Retinal Vein Occlusions Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Allergan
  • Bayer AG
  • IRIDEX Corporation
  • Lumenis
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Merck & Co.
  • Carl Zeiss
  • AbbVie Inc.
  • CalciMedica Inc.
  • Outlook Therapeutics, Inc.
  • Kodiak Sciences Inc.
  • Aerie Pharmaceuticals Inc.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

Table of Contents

180 Pages
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Retinal Vein Occlusion Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Retinal Vein Occlusion Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.1 Germany Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.2 France Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.3 Italy Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.4 Spain Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
5.4 Japan Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
6 Retinal Vein Occlusion Market Overview – 7MM
6.1 Retinal Vein Occlusion Market Historical Value (2017-2023)
6.2 Retinal Vein Occlusion Market Forecast Value (2024-2032)
7 Retinal Vein Occlusion Market Landscape – 7MM
7.1 Retinal Vein Occlusion Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Retinal Vein Occlusion Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Type
7.2.3 Analysis by Route of Administration
8 Retinal Vein Occlusion Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Retinal Vein Occlusion Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Retinal Vein Occlusion Market Segmentation – 7MM
11.1 Retinal Vein Occlusion Market by Type
11.1.1 Market Overview
11.1.2 Branch Retinal Artery Occlusion
11.1.3 Central Retinal Vein Occlusion
11.2 Retinal Vein Occlusion Market by Condition
11.2.1 Market Overview
11.2.2 Non-Ischemic
11.2.3 Ischemic
11.3 Retinal Vein Occlusion Market by Diagnosis
11.3.1 Market Overview
11.3.2 Optical Coherence Tomography (OCT)
11.3.3 Fundoscopic Examination
11.3.4 Fluorescein Angiography
11.3.5 Others
11.4 Retinal Vein Occlusion Market by Treatment Type
11.4.1 Market Overview
11.4.2 Antivascular Endothelial Growth Factor
11.4.3 Corticosteroid Drugs
11.4.4 Laser Retinal Photocoagulation
11.4.5 Others
11.5 Retinal Vein Occlusion Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Clinics
11.5.4 Ambulatory Surgical Centers
11.5.5 Homecare Settings
11.5.6 Others
11.6 Retinal Vein Occlusion Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Retinal Vein Occlusion Market
12.1 Retinal Vein Occlusion Market Historical Value (2017-2023)
12.2 Retinal Vein Occlusion Market Forecast Value (2024-2032)
12.3 Retinal Vein Occlusion Market by Disease Type
12.4 Retinal Vein Occlusion Market by Treatment Type
13 EU-4 and United Kingdom Retinal Vein Occlusion Market
13.1 Retinal Vein Occlusion Market Historical Value (2017-2023)
13.2 Retinal Vein Occlusion Market Forecast Value (2024-2032)
13.3 Germany Retinal Vein Occlusion Market Overview
13.3.1 Retinal Vein Occlusion Market by Disease Type
13.3.2 Retinal Vein Occlusion Market by Treatment Type
13.4 France Retinal Vein Occlusion Market Overview
13.4.1 Retinal Vein Occlusion Market by Disease Type
13.4.2 Retinal Vein Occlusion Market by Treatment Type
13.5 Italy Retinal Vein Occlusion Market Overview
13.5.1 Retinal Vein Occlusion Market by Disease Type
13.5.2 Retinal Vein Occlusion Market by Treatment Type
13.6 Spain Retinal Vein Occlusion Market Overview
13.6.1 Retinal Vein Occlusion Market by Disease Type
13.6.2 Retinal Vein Occlusion Market by Treatment Type
13.7 United Kingdom Retinal Vein Occlusion Market Overview
13.7.1 Retinal Vein Occlusion Market by Disease Type
13.7.2 Retinal Vein Occlusion Market by Treatment Type
14 Japan Retinal Vein Occlusion Market
14.1 Retinal Vein Occlusion Market Historical Value (2017-2023)
14.2 Retinal Vein Occlusion Market Forecast Value (2024-2032)
14.3 Retinal Vein Occlusion Market by Disease Type
14.4 Retinal Vein Occlusion Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Allergan
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Bayer AG
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 IRIDEX Corporation
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Lumenis
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Novartis AG
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 F. Hoffmann-La Roche Ltd
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Regeneron Pharmaceuticals
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Merck & Co.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Carl Zeiss
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 AbbVie Inc.
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 CalciMedica Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Outlook Therapeutics, Inc.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Kodiak Sciences Inc.
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Aerie Pharmaceuticals Inc.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
21 Retinal Vein Occlusion Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us